ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer

Zhang, Guian; Luo, Yong*南方医科大学; y
International Journal of General Medicine2021DOI: 10.2147/IJGM.S336757
1被引10阅读
引用收藏
分享

摘要

Purpose: This study aims to construct an immune-related signature to provide comprehensive insights into the immune landscape of prostate cancer, which can predict biochemical recurrence (BCR) and clinical treatment. @@@ Methods: Based on The Cancer Genome Atlas (TCGA) dataset, a signature constructed by DEirlncRNAs pairs was determined. The receiver operating characteristic curve analysis, Kaplan-Meier analysis, nomogram, and decision curve analysis were used to analyze it. Then, immunophenoscore (IPS), immune cell infiltration, tumor mutation burden (TMB), and immune function were investigated. Finally, we evaluated the role of the signature in medical treatment. @@@ Results: A signature constructed by 10 valid DEirlncRNAs pairs was identified in the training set and validated well in the testing and entire set. The signature was a reliable and independent prognostic indicator to predict the BCR of prostate cancer, which was better than the clinicopathological characteristics. After dividing the patients into low- and high-risk groups by median value, we found that the high-risk group had shorter BCR-free time and higher TMB levels. Furthermore, the high-risk group was negatively associated with plasma B cells and CD+8 T cells. IPS and immune functions, such as immune checkpoints and human leukocyte antigen, were significantly different between the two groups. Low-risk group was more sensitive to endocrine therapy and immunotherapy, while high-risk group was more inclined to targeted drugs. Both groups had their own sensitive chemotherapy. @@@ Conclusion: We established a novel signature to predict BCR and validated its role in the immune landscape of prostate cancer, which could help patients receive personalized medical treatment.

学科与关键词

关键词
prostate cancerlncRNAbiochemical recurrenceTMBimmune landscapemedical treatment
相关
加载中…
  • Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy
    Luo, Yong; Liu, Xiaopeng; Lin, Jingbo*; Zhong, Weide*; Chen, Qingbiao*Mathematical Biosciences and Engineering, 2022, 19(11): 11345-11366.
  • Characterization of a Pyroptosis-Related Signature for Prognosis Prediction and Immune Microenvironment Infiltration in Prostate Cancer
    Zhang, Guian; Luo, Yong; Dong, Weimin; Zhong, Weide*Computational and Mathematical Methods in Medicine, 2022, 2022: 8233840.被引 4
  • Novel immune-related signature for risk stratification and prognosis in prostatic adenocarcinoma
    Zhao, Hai-Bo; Zeng, Yan-Ru; Han, Zhao-Dong; Zhuo, Yang-Jia; Liang, Ying-Ke; Hon, Chi Tin; Wan, Song; Wu, Shulin; Dahl, Douglas; Zhong, Wei-De*; Wu, Chin-Lee*Cancer Science, 2021, 112(10): 4365-4376.被引 8
查看全部 →

发表信息

论文状态
公开发表
期刊
International Journal of General Medicine
发表日期
2021
卷期
第 14 卷
页码
9031-9049
DOI
10.2147/IJGM.S336757
期刊收录
NSL
期刊等级
3区
成果收录
SCIE

作者

  • Z

    Zhang, Guian (第一作者)

  • L

    Luo, Yong (通讯)

    2 · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417